Engene Therapeutics Inc Net Income per Employee (ENGN), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Engene Therapeutics Inc   (NASDAQ: ENGN)
 

Engene Therapeutics Inc Net Income per Employee

ENGN's Quarterly Results, Trends, Rankings, Statistics
Engene Therapeutics Inc recorded a cumulative net loss of $-10 million during 12 month ending in the third quarter 2026.
The Healthcare sector has seen employees of 8 other companies achieving higher income per employee. While Engene Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 276 to 277.


What is Income per Employee Ratio?






ENGN Net Income per Employee (Jul 31 2026)
III. Quarter
(Apr 30 2026)
II. Quarter
(Jan 31 2026)
I. Quarter
(Oct 31 2025)
IV. Quarter
(Jul 31 2025)
III. Quarter
Y / Y Net Income Change - - 20.86 % - 104.91 %
Net Income per Employee (TTM) $ -126,854 623,049 -60,390 -123,024 525,500
ENGN's Total Ranking # 277 # 276 # 93 # 0 # 0
Seq. Net Income Change - 1.6 % - - -


ENGN Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 39
Overall Market # 277

Net Income per Employee Statistics
High Average Low
$ 842,037 $ 337,159 $ -126,854
(Jan 31 2025)   (Jul 31 2026)







Companies with similar Income per Employee for 12 month ending Jul 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Jul 31 2026Number of Employees Jul 31 2026


Date modified: 2026-09-10T01:27:28+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.